![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Opti Medical Systems’ COVID-19 Influenza A and B Diagnostic Gets EUA
Opti Medical Systems’ COVID-19 Influenza A and B Diagnostic Gets EUA
The FDA has granted Emergency Use Authorization to Opto Medical Systems’ diagnostic test for COVID-19 and influenza A and B.
The OPTI SARS-CoV-2/ Influenza A/B test is authorized for detection and differentiation of SARS-CoV-2, influenza A and/or influenza B virus RNA in nasopharyngeal swab specimens collected from people suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider.
Emergency use of the real-time polymerase chain-reaction (RT-PCR) test is limited to laboratories that meet requirements to perform high-complexity tests, the agency said.
Related Events
Upcoming Events
-
11Jul
-
18Jul
-
21Oct